ENOXACIN GLUCONATE

US Previously Marketed

First approved in 1991

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H17FN4O3.C6H12O7
Molecular Weight	516.4742
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.CCN1C=C(C(O)=O)C(=O)C2=CC(F)=C(N=C12)N3CCNCC3

InChI

InChIKey=UQCAODSJNCBXEG-IFWQJVLJSA-N

InChI=1S/C15H17FN4O3.C6H12O7/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20;7-1-2(8)3(9)4(10)5(11)6(12)13/h7-8,17H,2-6H2,1H3,(H,22,23);2-5,7-11H,1H2,(H,12,13)/t;2-,3-,4+,5-/m.1/s1

HIDE SMILES / InChI

Description
Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6226242 | https://www.ncbi.nlm.nih.gov/pubmed/8429114 | https://www.ncbi.nlm.nih.gov/pubmed/8494374

Enoxacin is an oral broad-spectrum fluoroquinolone antibacterial agent used in the treatment of urinary tract infections and gonorrhea. Enoxacin is bactericidal drugs, eradicating bacteria by interfering with DNA replication. Like other fluoroquinolones, enoxacin functions by inhibiting bacterial DNA gyrase and topoisomerase IV. The inhibition of these enzymes prevents bacterial DNA replication, transcription, repair and recombination. Enoxacin is active against many Gram-positive bacteria. After oral administration enoxacin is rapidly and well absorbed from the gastrointestinal tract. The antibiotic is widely distributed throughout the body and in the different biological tissues. Tissue concentrations often exceed serum concentrations. The binding of enoxacin to serum proteins is 35 to 40%. The serum elimination half-life, in subjects with normal renal function, is approximately 6 hours. Approximately 60% of an orally administered dose is excreted in the urine as unchanged drug within 24 hours. Enoxacin, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. The compound should not be administered to patients with epilepsy or a personal history of previous convulsive attacks as may promote the onset of these disorders.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363077 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18813225	Inhibitor 8297
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9341164	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus 3 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991
Complicated urinary tract infections 11 Sources: http://www.rxlist.com/penetrex-drug/indications-dosage.htm	Curative	Approved 8429	PENETREX Approved Use INDICATIONS AND USAGE. Uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae. Uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis*, or Staphylococcus saprophyticus. Complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae. Launch Date 1991

C_max

Value	Dose	Analyte	Population
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
0.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.58 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.02 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.83 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
25.75 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
29.08 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.67 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.35 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	4-OXO-ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	800 mg single, intravenous dose: 800 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162901	200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	ENOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	400 mg 2 times / day steady-state, oral dose: 400 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3162904	600 mg 2 times / day steady-state, oral dose: 600 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ENOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 41.9 years n = 79 Health Status: unhealthy Condition: cystitis Age Group: 41.9 years Sex: M+F Population Size: 79 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	unhealthy, 43.8 years n = 75 Health Status: unhealthy Condition: cystitis Age Group: 43.8 years Sex: M+F Population Size: 75 Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/	Sources: https://pubmed.ncbi.nlm.nih.gov/2764538/
600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	Other AEs: Gastrointestinal disorders, Epidermal and dermal conditions... Other AEs: Gastrointestinal disorders (1.3%) Epidermal and dermal conditions (0.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

AEs

AE	Significance	Dose	Population
Epidermal and dermal conditions	0.4%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/
Gastrointestinal disorders	1.3%	600 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 600 mg, 3 times / day Route: oral Route: multiple Dose: 600 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/	unhealthy, adult n = 20060 Health Status: unhealthy Condition: Gram-negative urinary tract pathogens Age Group: adult Sex: M+F Population Size: 20060 Sources: https://pubmed.ncbi.nlm.nih.gov/8741236/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 P-gp 1461	MATE1 135 OATP1A2 62	CYP1A2 701 CYP2B1 26 CYP2B2 15 CYP2E1 128 CYP3A1 4 CYP3A2 6 CYP4A1 17 CYP1A1 108

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A1 218	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B1 41	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2B2 16	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP2E1 970	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A1 5	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP3A2 13	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
CYP4A1 25	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15543082/	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/	yes [Inhibition 250 uM]	yes (co-administration study) Comment: enoxacin caused a 6-fold decrease in caffeine clearance Sources: https://pubmed.ncbi.nlm.nih.gov/8347124/;https://pubmed.ncbi.nlm.nih.gov/10096258/
CYP1A2 1692	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/7503804/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
MATE1 135	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/19004926/	yes
OATP1A2 62	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565919/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:157175	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:157175
ChemicalBook	CB2403021	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2403021
MolPort	MolPort-003-666-456	https://www.molport.com/shop/molecule-link/MolPort-003-666-456
Selleck Chemicals	Enoxacin(Penetrex)	http://www.selleckchem.com/products/Enoxacin(Penetrex).html
ZINC	ZINC000019594549	http://zinc15.docking.org/substances/ZINC000019594549
eMolecules	538022	https://www.emolecules.com/cgi-bin/more?vid=538022

PubMed

Title	Date	PubMed
Assessment of temafloxacin neurotoxicity in rodents.	1991 Dec 30	1662895
Hippocampus and frontal cortex are the potential mediatory sites for convulsions induced by new quinolones and non-steroidal anti-inflammatory drugs.	1991 Jun	1651287
Interaction of the new quinolone antibacterial agent levofloxacin with fenbufen in mice.	1992 Mar	1622442
Enoxacin acute liver injury.	1992 May	1506651
[The history of the development and changes of quinolone antibacterial agents].	2003	15143768
Enoxacin trihydrate.	2004 Apr	15071236
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.	2004 Apr	15047530
Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture.	2004 Apr-Jun	15244525
Validation of HPLC method for determination of six fluoroquinolones: cinoxacin, ciprofloxacin, enoxacin, lomefloxacin, norfloxacin and ofloxacin.	2004 Dec	15909943
Sensitivity and spectrum of bacterial isolates in infectious otitis externa.	2004 Mar	15228846
Spectroscopic properties of various quinolone antibiotics in aqueous-organic solvent mixtures.	2004 Nov-Dec	15623343
Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux.	2004 Nov-Dec	15543082
[Simultaneous determination of quinolones in foods by LC/MS/MS].	2004 Oct	15678937
A novel approach to estimate in vitro antibacterial potency of Chinese medicine using a concentration-killing curve method.	2005	16173540
Determination of fluoroquinolones in edible animal tissue samples by high performance liquid chromatography after solid phase extraction.	2005 Apr	15881086
Evaluation of phototoxic and photoallergic potentials of 13 compounds by different in vitro and in vivo methods.	2005 Apr 4	15792876
HPLC determination of enoxacin, ciprofloxacin, norfloxacin and ofloxacin with photoinduced fluorimetric (PIF) detection and multiemission scanning: application to urine and serum.	2005 Aug 5	16006203
Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro.	2005 Dec	16539034
Validation of a novel HPLC sorbent material for the determination of ten quinolones in human and veterinary pharmaceutical formulations.	2005 Dec	16405173
Preparation and evaluation of sustained ophthalmic gel of enoxacin.	2005 Dec	16316852
Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice.	2005 Jan 10	15659296
Structure-phototoxicity relationship in Balb/c mice treated with fluoroquinolone derivatives, followed by ultraviolet-A irradiation.	2005 Jul 4	15917145
Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.	2005 Jul-Aug	15691228
Flow-injection electrogenerated chemiluminescence determination of fluoroquinolones based on its sensitizing effect.	2005 Jul-Oct	16134218
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Interaction study between enoxacin and fluvoxamine.	2005 Jun	15905806
Direct determination of five fluoroquinolones in chicken whole blood and in veterinary drugs by HPLC.	2005 Mar	15792246
Antibacterial studies, DNA oxidative cleavage, and crystal structures of Cu(II) and Co(II) complexes with two quinolone family members, ciprofloxacin and enoxacin.	2005 Mar	15708788
Antimicrosporidial activity of (fluoro)quinolones in vitro and in vivo.	2005 May	16004377
Fluoroquinolone-resistant Campylobacter isolates from conventional and antibiotic-free chicken products.	2005 May	15866763
Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.	2005 May	15848290
Vibrational spectroscopic characterization of fluoroquinolones.	2005 May	15820884
Separation and determination of seven fluoroquinolones by pressurized capillary electrochromatography.	2005 Nov	16318219
[Determination of enoxacin in urine by synchronous fluorimetry].	2005 Oct	16395901
Bench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.	2005 Oct 5	16277734
Effect of fluoroquinolones on plasma glucose levels in fasted and glucose-loaded mice.	2006 Apr	16648952
Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.	2006 Apr	16171969
Simultaneous determination of (fluoro)quinolone antibiotics in kidney, marine products, eggs, and muscle by enzyme-linked immunosorbent assay (ELISA).	2006 Apr 19	16608195
Antimicrobial drug resistance, regulation, and research.	2006 Feb	16494740
Genotoxic potential of quinolone antimicrobials in the in vitro comet assay and micronucleus test.	2006 Feb 28	16384725
Radiation-induced in vitro phototoxic potential of some fluoroquinolones.	2006 Jan	16455588
Effects of Transcutol P on the corneal permeability of drugs and evaluation of its ocular irritation of rabbit eyes.	2006 Jan	16393463
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.	2006 Jan	16393267
Photophysics and photochemistry of nalidixic acid.	2006 Jan-Feb	16107187
A batch chemiluminescence determination of enoxacin using a tris-(1,10-phenanthroline)ruthenium(II)-cerium(IV) system.	2006 Jul	16794867
Quinolones for uncomplicated acute cystitis in women.	2006 Jul 19	16856014
[Study on interaction of caffeine and theophylline with bovine serum albumins].	2006 Mar	16830766
Electrochemiluminescence of terbium (III)-two fluoroquinolones-sodium sulfite system in aqueous solution.	2006 May 1	16098798
A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements.	2006 Oct 11	16765011
Induction of keratinocyte apoptosis by photosensitizing chemicals plus UVA.	2007 Feb	17141480

Patents

Sample Use Guides

In Vivo Use Guide

Enoxacin should be taken at least one hour before or at least two hours after a meal. For treatment uncomplicated urethral or cervical gonorrhea: 400 mg single dose. For treatment uncomplicated urinary tract infections 200 mg q12h for 7 days. For treatment complicated urinary tract infections: 400 mg q12h for 14 days. Dosage should be adjusted in patients with a creatinine clearance value of 30 mL/min/1.73 m 2 or less.

Route of Administration: Oral

In Vitro Use Guide

The in vitro antibacterial activity of AT-2266 (Enoxacin ) was tested by the determination of minimal bactericidal concentrations (MBCs) and the reduction of viable cells during exposure to the drug for 24 h. MIC90s of AT-2266 for P. aeruginosa resistant to gentamicin and Enterobacteriaceae resistant to nalidixic acid were 3.13 and 12.5 mkg/ml, respectively

Name

Type

Language

ENOXACIN GLUCONATE

Common Name

English

D-GLUCONIC ACID, COMPD. WITH 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID (1:?)

Systematic Name

English

Enoxacin gluconate [WHO-DD]

Common Name

English

ENOXACIN GLYCONATE

Common Name

English

D-GLUCONIC ACID, COMPD. WITH 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID

Systematic Name

English

D-GLUCONIC ACID, COMPD. WITH 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID (1:1)

Systematic Name

English

Code System Code Type Description

FDA UNII

FK8O5WLR9H